Disopyramide Phosphate
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Disopyramide Phosphate
- Disopyramide Phosphate: Antiarrhythmic Agent — No Repurposing Predictions Available
Disopyramide Phosphate: Antiarrhythmic Agent — No Repurposing Predictions Available
One-Sentence Summary
Disopyramide Phosphate is a Class Ia antiarrhythmic agent classically used to manage ventricular and supraventricular arrhythmias. The current Evidence Pack contains no TxGNN-predicted new indications for this drug, and critical data gaps — including mechanism of action details and safety warnings — remain unresolved. A complete repurposing evaluation cannot proceed until these gaps are addressed.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Cardiac arrhythmias (antiarrhythmic) |
| Predicted New Indication | No predictions available |
| TxGNN Prediction Score | — |
| Evidence Level | — |
| New Zealand Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Drug Background
There are currently no TxGNN repurposing predictions for Disopyramide Phosphate. The following provides pharmacological background to support future evaluation once predictions are generated.
Disopyramide Phosphate is a Class Ia antiarrhythmic agent that works by blocking fast sodium channels in cardiac myocytes, prolonging the action potential duration and effective refractory period, and thereby suppressing ectopic pacemaker activity. It also exerts anticholinergic (atropine-like) effects. Clinically, it has historically been used for ventricular tachycardia, ventricular fibrillation prevention, and atrial fibrillation/flutter conversion.
Detailed mechanism of action data is not yet available in this Evidence Pack. The query log indicates that a DrugBank query for this drug returned 1 result, but the data has not yet been integrated. Once MOA details are retrieved and TxGNN predictions are generated, a mechanism-based rationale for any predicted new indication can be established.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
New Zealand Market Information
Disopyramide Phosphate is currently not marketed in New Zealand. No product authorizations have been identified in the regulatory database.
Safety Considerations
Please refer to the package insert for safety information.
The query log confirms that a TFDA package insert record was located (1 result), but key warnings and contraindications have not yet been extracted into the Evidence Pack. Drug interaction database query returned no results. These gaps must be resolved before any clinical evaluation can proceed.
Conclusion and Next Steps
Decision: Hold
Rationale: No TxGNN repurposing predictions exist for this drug at this time, and both safety data and mechanistic data remain unresolved; there is no actionable repurposing candidate to evaluate.
To proceed, the following is needed:
- Run TxGNN prediction pipeline for Disopyramide Phosphate to generate repurposing candidates
- Integrate DrugBank data — the query log shows 1 DrugBank record was retrieved (2026-03-29) but not yet parsed into the Evidence Pack; extract MOA, categories, and toxicity data
- Extract package insert content — TFDA package insert query returned 1 result (2026-03-29); parse key warnings, contraindications, and dosing restrictions from the PDF
- Re-query drug interaction database — current DDI query returned no results; consider alternative sources (e.g., Drugs.com, MICROMEDEX) given Disopyramide's known interaction profile with Class I antiarrhythmics and anticholinergic agents
- Assess New Zealand registration pathway — if a viable repurposing candidate is identified after the above steps, evaluate Medsafe registration requirements
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.